Our research found that compared with high-dose anti-VEGFR2 combined with anti-PD-1, low-dose anti-VEGFR2 combined with anti-PD-1 down-regulated the expression of LAYN on tumor infiltrating exhausted CD8+T cells, increased the secretion of GZMB, and then enhanced the function of CD8+T cells. Here, PDCD1 is linked to neoplasm.